Clearline Capital LP - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 98 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2019. The put-call ratio across all filers is 6.05 and the average weighting 0.4%.

Quarter-by-quarter ownership
Clearline Capital LP ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q3 2021$4,276,000
+603.3%
577,800
+1450.8%
0.40%
+35.7%
Q2 2019$608,000
-89.3%
37,258
-92.8%
0.30%
-69.0%
Q3 2015$5,680,000
-10.6%
516,804
+5.9%
0.96%
+8.4%
Q2 2015$6,354,000
+50.3%
487,992
+100.2%
0.88%
+39.7%
Q1 2015$4,228,000
+13.1%
243,706
-2.7%
0.63%
+9.1%
Q4 2014$3,738,000250,5500.58%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q2 2019
NameSharesValueWeighting ↓
Chescapmanager LLC 1,157,718$17,117,0002.77%
Baupost Group 8,735,168$129,149,0001.40%
Orbimed Advisors 6,219,110$91,950,0001.16%
Rubric Capital Management LP 550,747$8,143,0000.76%
Cormorant Asset Management, LP 650,072$9,611,0000.37%
Rock Springs Capital Management LP 824,018$12,183,0000.31%
Virtus ETF Advisers LLC 23,148$342,0000.18%
Tekla Capital Management LLC 298,470$4,413,0000.16%
PEREGRINE CAPITAL MANAGEMENT LLC 412,594$6,100,0000.16%
NJ State Employees Deferred Compensation Plan 38,142$564,0000.10%
View complete list of THERAVANCE BIOPHARMA INC shareholders